Facebook pixel for internal purposes

One World Medicine

Tamil Nadu

Dr. Shiva Ayyadurai

Using his extensive background in medicine, tech and innovation, Dr. Shiva Ayyadurai has created a digital platform to connect and inform Indian communities on their cultural traditions in medicine, Ayurveda, science, and arts. By using modern media, he strives to bring out the history of regions across the country in a new way to keep people educated.

15:24 | 2014

Go back to show page

Share

About Shiva Ayyadurai

Dr. V.A. Shiva Ayyadurai, the inventor of email and polymath, holds four degrees from MIT, is a world-renowned systems scientist, inventor and entrepreneur. His love of medicine and complex systems began in India when he became intrigued with medicine at the age of five as he observed his grandmother, a farmer and healer in the small village of Muhavur in South India, apply Siddha, India’s oldest system of traditional medicine, to heal and support local villagers. These early experiences inspired him to pursue the study of modern systems science, information technology and eastern and traditional systems of medicine to develop an integrative framework linking eastern and western systems of medicine.

In 1978, as a precocious 14-year-old, after completing a special program in computer science at the Courant Institute of Mathematical Science at NYU, Ayyadurai was recruited by the University of Medicine and Dentistry of New Jersey (UMDNJ) as a Research Fellow, where he developed the first electronic emulation of the entire interoffice mail system (Inbox, Outbox, Folders, Address Book, Memo, etc.), which he named “EMAIL,” to invent the world’s first email system, resulting in him being awarded the first United States Copyright for Email, Computer Program for Electronic Mail System, at a time when Copyright was the only protection for software inventions.

Today, he is the Chairman & CEO of CytoSolve, Inc. CytoSolve provides a revolutionary platform for modeling complex diseases as well as for discovering multi-combination therapeutics. His recent efforts at CytoSolve have led to an FDA allowance and exemption for a multi-combination drug for pancreatic cancer, development of innovative nutraceutical products, as well as numerous industry and academic partnerships.

Visit his website https://vashiva.com/

CORE iOS App CORE Android App